Clinical Trials Results
|
Results for the search you initiated will be displayed below.
-
Click here for details...
This phase III trial compares perioperative chemotherapy (given before and after surgery)
versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer
that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as
fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively)
may work better in treating patients with pancreatic cancer compared to giving chemotherapy
after surgery (adjuvantly).
-
Click here for details...
This phase II trial compares capecitabine and temozolomide to lutetium Lu 177 dotatate for
the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body
(advanced) or are not able to be removed by surgery (unresectable). Chemotherapy drugs, such
as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly
to tumor cells and may reduce harm to normal cells. The purpose of this study is to find out
whether capecitabine and temozolomide or lutetium Lu 177 dotatate may kill more tumor cells
in patients with advanced pancreatic neuroendocrine tumors.
-
Click here for details...
This phase II trial compares two treatment combinations: gemcitabine hydrochloride and
nab-paclitaxel, or fluorouracil, leucovorin calcium, and liposomal irinotecan in older
patients with pancreatic cancer that has spread to other places in the body (metastatic).
Drugs used in chemotherapy, such as gemcitabine hydrochloride, nab-paclitaxel, fluorouracil,
leucovorin calcium, and liposomal irinotecan, work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
from spreading. This study may help doctors find out which treatment combination is better at
prolonging life in older patients with metastatic pancreatic cancer.
-
Click here for details...
This phase II trial investigates how well the addition of olaparib following completion of
surgery and chemotherapy works in treating patients with pancreatic cancer that has been
surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2.
Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA)
when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged
DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
-
Click here for details...
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works
better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or
BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are
human genes that produce tumor suppressor proteins. These proteins help repair damaged
deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each
cell's genetic material. When either of these genes is mutated, or altered, such that its
protein product is not made or does not function correctly, DNA damage may not be repaired
properly. As a result, cells are more likely to develop additional genetic alterations that
can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal
antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of
PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from
repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted
therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink
tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
-
Click here for details...
This phase II trial studies the effect of capecitabine and temozolomide after surgery in
treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving capecitabine and temozolomide after surgery could
prevent or delay the return of cancer in patients with high-risk well-differentiated
pancreatic neuroendocrine tumors.
|
